Company intelligence / Profile preview

Abcely

Nantes, Pays de la Loire, Franceabcely.com ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

Abcely has developed ABC-101, the first orally active class A monoclonal antibody targeting CEA for mucosal cancers. In preclinical models of advanced metastatic colorectal cancer (CRC), oral ABC-101 was well tolerated and demonstrated superior tumor reduction compared to standard IV-administered IgG therapies like Erbitux®, both as monotherapy and in combination with irinotecan. The company is currently accelerating pre-clinical development following a recent funding round to prepare for regulatory trials[1][5].

Therapeutic areas: OncologyImmunologyWomen's Health
Modalities: Oral monoclonal IgA antibodies (secretory IgA, sIgA)
Industry: Biotech

Drug pipeline

3 assets

ABC-201

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

3Biotech (backer/investor; contributed to CMC development plan and early production/purification/analysis phases)[5]CRO specializing in pre-industrial production/purification/analysis of biological molecules [5]

Beyond the preview

Go deeper on Abcely.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Abcely.

Explore the full profile